Show simple item record

dc.contributor.advisorStar, Khoza
dc.contributor.authorAudrey Masindi, Mutshidzi
dc.date.accessioned2024-01-22T14:08:02Z
dc.date.available2024-01-22T14:08:02Z
dc.date.issued2024
dc.identifier.urihttp://hdl.handle.net/11394/10617
dc.description>Magister Scientiae - MScen_US
dc.description.abstractPurpose: Although chemotherapeutic drugs have improved the survival rate of patients diagnosed with colorectal cancer, resistance to chemotherapy frequently leads to therapeutic failure and poor patient outcomes. Multidrug resistance (MDR) is a serious threat to cancer treatment efficacy and may be linked to the overexpression of drug efflux pumps. P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. This has led to an interest in chitosan alginate nanoparticles (CANPs) as novel anticancer drug carriers and curcumin (CUR) as an inhibitor of P-gp. Chitosan (CS) and alginate (ALG) are among the most extensively used polymers for nanoparticle (NP) preparation as they possess excellent non-toxic and biodegradable characteristics. The aim of this study was to investigate the effect of DOX encapsulated CANPs and CUR on MDR colon cancer cell lines (Caco-2 cells).en_US
dc.language.isoenen_US
dc.publisherUniversity of the Western Capeen_US
dc.subjectCanceren_US
dc.subjectChitosanen_US
dc.subjectAlginateen_US
dc.subjectNanoparticlesen_US
dc.subjectDoxorubicinen_US
dc.titleThe effect of doxorubicin encapsulated chitosan alginate nanoparticles and curcumin on multidrug resistant colon cancer cell linesen_US
dc.rights.holderUniversity of the Western Capeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record